RecruitingPhase 3NCT04976153

Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence

Skeletal Muscle-derived Cell Implantation for the Treatment of Fecal Incontinence: a Phase III, Randomized, Controlled, Double Blind, Two Armed Clinical Study


Sponsor

Innovacell GmbH

Enrollment

290 participants

Start Date

May 11, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of this study is the final assessment of clinical safety and efficacy of autologous autologous skeletal muscle derived cells for patients with urge fecal incontinence due to external anal sphincter dysfunction caused by its disruption and/or weakness.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Patients must be at least 18 years old
  • Patients who are mentally competent and able to understand all study requirements
  • Female patients of childbearing potential willing to use appropriate methods of contraception
  • Patient has symptoms of urge fecal incontinence with a disease duration of at least 6 months and did not improve sufficiently by conservative treatment performed for at least 3 months
  • Urge fecal incontinence episodes that occur more than twice a week
  • Maximal incremental voluntary squeeze pressure (increase to resting pressure) on anal manometry is 100mmHg or less in women and 150mmHg or less in men
  • \. Ultrasound of the anal canal showing intact external anal sphincter or a maximal overall extent of external anal sphincter injury and tear of 180 degrees

Exclusion Criteria19

  • Patients for whom the investigator determines that FI has a different cause than external anal sphincter dysfunction.
  • Patients with global fragmentation of the external anal sphincter as assessed by anal canal ultrasound
  • Patients who underwent any anorectal surgery within 6 months before screening visit
  • Patients who underwent a total of two or more external anal sphincter-related surgeries
  • Patients who currently have anal fistulas or fissures or have recurrent anal fistulas or fissures
  • Patients with poorly controlled chronic constipation including obstructed defecation syndrome
  • Patients with indications against a surgery under anesthesia
  • Patients with a malignant disease not in remission for 5 years or more
  • Patients who have undergone radiation therapy of the bowel and pelvis
  • Patients who have undergone chemotherapy within last 5 years prior to study enrolment and/or chemotherapy related neuropathy of the bowel and pelvis
  • Patients with compromised immune system and/or rheumatic disease, and patients under immunosuppressive therapy
  • Patients with a diagnosis of chronic inflammatory bowel disease (e.g Crohn's disease, Colitis Ulcerosa)
  • Patients suffering from a disease which has not been resolved within 4 weeks prior to screening including fever and/or diarrhea of unknown reasons (4 weeks)
  • Patients diagnosed with human immunodeficiency virus (HIV), acute or chronic viral hepatitis HCV, acute or chronic viral hepatitis HBV, active Syphilis or HTLV (tested upon risk assessment by investigator)
  • Patients diagnosed with any kind of skeletal muscle disease and/or neuronal disorders
  • Patients with severe myocardial disorders, irregular pulse or a pacemaker
  • Patients with implantations of metal components in the electrical stimulation treatment area
  • Patients with uncontrolled diabetes mellitus type I or II, or suffering from diabetic peripheral neuropathic pain
  • Patients with clinically relevant abnormal laboratory values judged by the responsible investigator as relevant for the study treatment

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALaSMDC

Autologous Muscle Derived Cells for injection into the external anal sphincter

OTHERPlacebo

Placebo control is the vehicle solution used for the study product


Locations(31)

Landeskrankenhaus Feldkirch

Feldkirch, Austria

Medical University Graz

Graz, Austria

Medical Center Unimed EOOD

Sevlievo, Bulgaria

Fakultni nem. u sv. Anny v Brne

Brno, Brno, Czechia

The Institute for the Care of Mother and Child

Prague, Czechia

Deaconess Hospital Group Croix Saint - Simon

Paris, France, France

Hospital Bichat - Claude Bernard

Paris, France, France

CHU Rennes - Hospital Pontchaillou

Rennes, France

CHU de Rouen

Rouen, France

Heidelberg University, Medical Faculty Mannheim, Department of surgery

Mannheim, Germany

IRCCS Ospedale San Raffaele

San Donato Milanese, Italy

Hokkaido Railway Company JR Sapporo Hospital

Sapporo, Hokkaido, Japan

Tsujinaka Hospital, Coloproctological Surgery

Chiba, Japan

Teikyo University Chiba Medical Center

Chiba, Japan

Kurume Hospital

Fukuoka, Japan

Hiroshima Memorial Hospital

Hiroshima, Japan

Meiwa Hospital

Hyōgo, Japan

Matsushima Hospital

Kanagawa, Japan

Coloproctology Center Takano Hospital

Kumamoto, Japan

Japan Post Kyoto Teishin Hospital

Kyoto, Japan

Jichi Medical University Hospital

Tochigi, Japan

Juntendo University Hospital

Tokyo, Japan

Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie

Krakow, Poland

Corporacio Sanitaria Parc Tauli

Barcelona, Spain

Hospital de Mataro

Mataró, Spain

Hosp. General Universitario Morales Meseguer

Murcia, Spain

Luis Garcia Florez

Oviedo, Spain

Skånes Universitetssjukhus, Malmo

Malmö, Sweden, Sweden

Östersund sjukhus, Kirurgiska kliniken

Östersund, Sweden, Sweden

Danderyd Sjukhus

Danderyd, Sweden

St. Mary's Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04976153


Related Trials